# A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

> **NCT07465835** · PHASE1 · RECRUITING · sponsor: **Electra Therapeutics Inc.** · enrollment: 84 (estimated)

## Conditions studied

- T Cell Malignancies

## Interventions

- **DRUG:** ELA026

## Key facts

- **NCT ID:** NCT07465835
- **Lead sponsor:** Electra Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-17
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465835, "A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07465835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*